The announcement of positive study results for Probudur by Virpax Pharmaceuticals is likely to be viewed positively by investors, as it highlights the company's progress in developing a potentially market-disrupting product. The focus on reducing or eliminating opioid use after surgery addresses a significant public health issue, potentially opening up a substantial market for Probudur if it is approved for use. This could lead to increased investor interest and a positive short-term impact on VRPX's stock price.